

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2410)

**INSIDE INFORMATION
APPLICATION FOR THE H SHARE FULL CIRCULATION
BY THE COMPANY**

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the **“Company”**) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Listing Rules”**) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the China Securities Regulatory Commission (the **“CSRC”**) Announcement [2019] No. 22 “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies”《(H股公司境內未上市股份申請“全流通”業務指引)》 issued by the CSRC on November 14, 2019 and amended on August 10, 2023 and the “Trial Administrative Measures for Overseas Securities Offering and Listing by Domestic Companies”《(境內企業境外發行證券和上市管理試行辦法)》 issued by the CSRC on February 17, 2023 regarding the guidelines for procedures to apply for full circulation of shares by companies whose H shares are listed on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**).

The board (the **“Board”**) of directors (the **“Directors”**) of the Company is pleased to announce that the Company has submitted an application (the **“Application”**) to the CSRC on June 6, 2025, in respect of the conversion of 4,608,000 unlisted shares (the **“Unlisted Shares”**) into H shares (the **“H Shares”**) of the Company and the listing of such shares on the Stock Exchange (the **“H Share Full Circulation”**). Subject to obtaining all the filings and/or approvals from relevant regulatory authorities (including but not limited to the CSRC and the Stock Exchange) and the compliance with all the applicable laws, regulations and rules, such Unlisted Shares shall be converted into H Shares and be eligible to be listed and traded on the Main Board of the Stock Exchange, details of which are as follows:

Name of shareholder	Number of Unlisted Shares to be converted into H Shares	Approximate percentage⁽¹⁾ of the Company's total issued share capital⁽²⁾
Zhuzhou Guohai Guochuang Qianjin Pharmaceutical Venture Capital Partnership (Limited Partnership)*/ 株洲市國海國創千金醫藥創業投資合夥企業 (有限合夥)	4,608,000	1.24%
Total	4,608,000	1.24%

Note:

- (1) The percentages have been rounded up to the nearest two decimal places.
- (2) The calculation is based on the total number of 370,835,818 shares of the Company in issue as of the date of this announcement.

Pursuant to the articles of association of the Company, no further shareholders' meeting is required to be convened to approve the H Share Full Circulation.

As of the date of this announcement, the Company has not completed the filing with the CSRC in respect of the Application. Further announcement(s) will be made on the progress and details of the Application and the H Share Full Circulation as and when appropriate.

The H Share Full Circulation is subject to other relevant procedures as required by the CSRC, the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, June 6, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng and Dr. JIANG Mingyu as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying and Mr. HE Chao as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.

* For identification purpose only